Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Bupivacaine vs. Bupivacaine + Dexmedetomidine in Orthopedic Surgeries
NCT07866508Phase 1Active, not recruiting
- Sponsor
- Sheikh Khalifa Bin Zayed Al Nahyan Combined Military Hospital Muzaffarabad
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dexmedetomidine in postoperative pain (2 arms), sponsored by Sheikh Khalifa Bin Zayed Al Nahyan Combined Military Hospital Muzaffarabad. Primary endpoint: Duration of Postoperative Analgesia at 12 hours. Started Aug 2026; status: active, not recruiting.
02
Drugs
dexmedetomidine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07866508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07866508.